Nanopath is dedicated to improving health equity worldwide, starting with women's health. Nanopath's proprietary molecular diagnostic test takes a radically new approach to how clinicians measure and characterize human health. Through its novel biosensing technology, the company has the potential to enable fast, high-complexity tests to be performed in minutes and at the point-of-care, rather than in centralized laboratories. Nanopath's founders seek to improve the lives of women and other underserved populations, while simultaneously enhancing the lives of the Nanopath team members through purpose-driven work that helps to develop and deploy its products.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/09/22 | $10,000,000 | Series A |
Gingerbread Capital Green D Ventures MedTech Venture Partners  Norwest Venture Partners | undisclosed |
